IOBT PE Ratio & Valuation, Is IOBT Overvalued

Historical Valuation

IO Biotech Inc (IOBT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.41. The fair price of IO Biotech Inc (IOBT) is between -- to -- according to relative valuation method.

Relative Value

Fair Zone

-----

Current Price：0.24

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is IO Biotech Inc (IOBT) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

IO Biotech Inc (IOBT) has a current Price-to-Book (P/B) ratio of 51.34. Compared to its 3-year average P/B ratio of 11.98, the current P/B ratio is approximately 328.73% higher. Relative to its 5-year average P/B ratio of 8.28, the current P/B ratio is about 519.93% higher. IO Biotech Inc (IOBT) has a Forward Free Cash Flow (FCF) yield of approximately -167.89%. Compared to its 3-year average FCF yield of -103.46%, the current FCF yield is approximately 62.28% lower. Relative to its 5-year average FCF yield of -86.41%, the current FCF yield is about 94.30% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for IOBT competitors is 1.72, providing a benchmark for relative valuation. IO Biotech Inc Corp (IOBT.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of IOBT increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of IOBT in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is IOBT currently overvalued or undervalued?

What is IO Biotech Inc (IOBT) fair value?

IOBT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of IO Biotech Inc (IOBT) is between to according to relative valuation method.

How does IOBT's valuation metrics compare to the industry average?

The average P/S ratio for IOBT's competitors is 1.72, providing a benchmark for relative valuation. IO Biotech Inc Corp (IOBT) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for IO Biotech Inc (IOBT) as of Mar 13 2026?

As of Mar 13 2026, IO Biotech Inc (IOBT) has a P/B ratio of 51.34. This indicates that the market values IOBT at 51.34 times its book value.

What is the current FCF Yield for IO Biotech Inc (IOBT) as of Mar 13 2026?

As of Mar 13 2026, IO Biotech Inc (IOBT) has a FCF Yield of -167.89%. This means that for every dollar of IO Biotech Inc's market capitalization, the company generates -167.89 cents in free cash flow.

What is the current Forward P/E ratio for IO Biotech Inc (IOBT) as of Mar 13 2026?

As of Mar 13 2026, IO Biotech Inc (IOBT) has a Forward P/E ratio of -1.19. This means the market is willing to pay $-1.19 for every dollar of IO Biotech Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for IO Biotech Inc (IOBT) as of Mar 13 2026?

As of Mar 13 2026, IO Biotech Inc (IOBT) has a Forward P/S ratio of 0.00. This means the market is valuing IOBT at $0.00 for every dollar of expected revenue over the next 12 months.

IOBT Valuation